X-linked hypophosphatemic rickets (XLH) is a rare inherited form of renal phosphate wasting disorder, but among the inherited forms it is the most common with an estimated prevalence of 1/20,000 births.
Diagnosis, when present, is based on a consistent medical history, physical examination, radiological evidence of rickets, biochemical exams and, when present, a family history suggestive of multigenerational or sporadic occurrence of XLH. Differential diagnosis includes nutritional rickets, metaphyseal dysplasia, and other forms of renal phosphate wasting disorders.

**Clinical Manifestations**

- **Cranial**
  - Frontal bossing
  - Craniosynostosis which can be associated with Chiari malformation
  - Hearing loss

- **Dental**
  - Dental abscesses
  - Enamel defects
  - Enlarged pulp chambers
  - Taurodontism

- **Skeletal and Joint**
  - Short stature
  - Lower limb deformities
  - Osteomalacia (including pseudofractures, early-onset osteoarthritis, enthesopathy leading to joint restriction)
  - Waddling gait
  - Bone and joint pain
  - Muscle pain and weakness
  - Spinal stenosis

- **Others**
  - Fatigue
  - Mobility restriction
  - Mental health issues
  - Diminished quality of life

**Laboratory Analysis**

<table>
<thead>
<tr>
<th>Serum values</th>
<th>Urine values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low phosphate*</td>
<td>Elevated or inappropriately normal phosphate***</td>
</tr>
<tr>
<td>Elevated bone alkaline phosphatase</td>
<td>Reduced TmP/GFR****</td>
</tr>
<tr>
<td>Normal calcium**</td>
<td></td>
</tr>
<tr>
<td>Normal PTH**</td>
<td></td>
</tr>
<tr>
<td>Normal 25(OH) vitamin D</td>
<td></td>
</tr>
<tr>
<td>Low or inappropriately normal 1,25(OH)(_2)D(_3)</td>
<td></td>
</tr>
<tr>
<td>Elevated intact FGF23*</td>
<td></td>
</tr>
</tbody>
</table>

*TmP/GFR: tubular maximal reabsorption of phosphate adjusted for glomerular filtration rate

*Fasting before sampling is required to give an accurate result

**Secondary hyperparathyroidism is common in patients with XLH, which can impact serum PTH and calcium concentration accordingly

*** Second morning void urine or urine collected over 24 hours

**** TmP/GFR is calculated from fasting paired plasma and second morning void urine samples obtained 2 hours after the first void urine for phosphate and creatinine

**Radiographic Evaluation**

- Pseudofractures
- Enthesopathy/mineralization of tendons and ligaments around the Achilles, knees, hips and spine
- Early-onset osteoarthritis

Beck Nielsen SS, et al., Orphanet J Rare Dis. 2019
XLH is caused by a variety of inactivating mutations in the \textit{PHEX} (phosphate regulating endopeptidase homolog X-linked) gene. This gene is located on chromosome Xp22.1, and is expressed in osteocytes and odontoblasts. The \textit{PHEX} gene codes for a transmembrane endopeptidase protein belonging to the type II integral membrane zinc-dependent endopeptidase family. Alternative splicing results in multiple transcript variants. More than 300 kinds of mutations have been reported. Other genetic and environmental factors may influence the clinical manifestations of this disease. Sporadic cases occur in about one third of individuals with XLH.

**GENETICS**

**PATHOPHYSIOLOGY**

Fibroblast growth factor 23 (FGF23), a hormone primarily secreted by osteocytes and osteoblasts, regulates phosphate metabolism together with parathyroid hormone (PTH) and 1,25(OH)\textsubscript{2}D\textsubscript{3}. Mutations of the \textit{PHEX} gene, which is highly expressed in these bone cells and teeth, lead to increased release of FGF23 into the serum and increased level of the FGF23-mediated signalling pathway. These link to impaired renal phosphate resorption by reducing the expression of the renal Na-Pi co-transporters (NPT2a, NPT2c).

In addition, FGF23 decreases the synthesis of 1,25(OH)\textsubscript{2}D\textsubscript{3} in the renal proximal tubules by downregulating CYP27B1 (encoding 1α-hydroxylase enzyme), leading to reduced conversion of 25(OH) vitamin D to 1,25(OH)\textsubscript{2}D\textsubscript{3}. FGF23 also upregulates CYP24A1 (encoding 24-hydroxylase enzyme), which converts 25(OH) vitamin D and 1,25(OH)\textsubscript{2}D\textsubscript{3} into inactive metabolites. Accordingly, decreased 1,25(OH)\textsubscript{2}D\textsubscript{3} results in decreasing phosphate absorption from the intestines.

**ALGORITHM FOR THE EVALUATION OF A PATIENT WITH LOW SERUM PHOSPHATE LEVELS**

- **Low serum phosphate**
  - **TmP/GFR**
    - **Normal**
      - Reduced intestinal phosphate absorption
      - Deficit in phosphate intake
      - Altered phosphate distribution in the body
      - Excessive wasting of phosphate from the body through extra-renal routes
    - **Low**
      - Hereditary hypophosphatemia with hypercalciuria
      - Fanconi syndrome
  - **Intact serum FGF23**
    - **Normal or low**
      - Hereditary hypophosphatemia
    - **Elevated**
      - Acquired hypophosphatemia (e.g., tumor-induced osteomalacia, intravenous iron-induced hypophosphatemia)
MANAGEMENT OF XLH

Patient education

• What is XLH?
• What are the typical signs and symptoms?
• What are the next steps for diagnosis and treatment initiation?
• How to manage complications and live with XLH
• How to receive support for patients and their families

Nonpharmacological management

• Lifestyle
  - Physical activity
  - Prevention and treatment of obesity
  - Control of risk factors (smoking, alcohol) and calcium intake
• Physiotherapy to manage musculoskeletal complications
• Management of dental health
• Management of hearing impairment

Pharmacological intervention

• Bone and joint pain control after identification of the cause of the pain
• Conventional treatment
  Oral phosphate supplementation and active vitamin D analogs
  These medications should be appropriately prescribed and monitored with regular follow-up, blood and urine examinations, including serum PTH and urinary calcium.
  In adults, these treatments are generally prescribed in the following cases:
  - Presence of clinical symptoms, especially osteomalacia with recurrent pseudo-fractures
  - Upcoming orthopaedic surgery
  - Biochemical evidence of osteomalacia with elevated ALP
  These medications should be discontinued one week prior to initiation of a monoclonal antibody for FGF23 (burosumab).

• Human monoclonal antibody for FGF23 (burosumab)
  Burosumab (CRYSVITA®) is a recombinant human monoclonal IgG1 antibody against FGF23. Initiation of burosumab is recommended in adults with XLH in the following cases:
  - Persistent bone and/or joint pain due to XLH and/or osteomalacia that limits daily activities
  - Insufficient response or refractory to conventional therapy
  - Complications related to conventional therapy
  The recommended starting dose of burosumab in adults is 1.0 mg/kg of body weight (maximum dose of 90 mg) every 4 weeks. Fasting serum phosphorus level should be monitored 2 weeks post-dose for the first 3 months of treatment.

Surgical intervention

• Orthopaedic surgery
  especially for:
  - Marked leg bowing with immediate functional consequences
  - Joint complications
• Neurosurgical posterior decompression
  - Spinal cord compression due to spinal stenosis

References:

2) Beck-Nielsen SS, et al. FGF23 and its role in X-linked hypophosphataemia-related morbidity. Orphanet J Rare Dis. 2019

Authored by IOF Skeletal Rare Diseases (SRD) Academy members
Prof. Nicholas Harvey, Prof. Maria Luisa Brandi, Dr. Manju Chandran, Prof. Roland Chapurlat, Prof. Serge Ferrari, Assoc.Prof. Kassim Javaid

Financedly supported by Kyowa Kirin, which had no input into the content or choice of author for the factsheet.